{"protocolSection":{"identificationModule":{"nctId":"NCT05153655","orgStudyIdInfo":{"id":"PROTECT"},"organization":{"fullName":"Capital Medical University","class":"OTHER"},"briefTitle":"Ischemic Post-conditioning in Acute Ischemic Stroke Thrombectomy","officialTitle":"Safety and Tolerability of Local Ischemic Post-conditioning in Patients With Acute Ischemic Stroke After Mechanical Thrombectomy","acronym":"PROTECT"},"statusModule":{"statusVerifiedDate":"2023-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-12-15","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-07-15","type":"ACTUAL"},"completionDateStruct":{"date":"2022-08-15","type":"ACTUAL"},"studyFirstSubmitDate":"2021-11-29","studyFirstSubmitQcDate":"2021-11-29","studyFirstPostDateStruct":{"date":"2021-12-10","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-01-02","lastUpdatePostDateStruct":{"date":"2023-01-04","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Ji Xunming,MD,PhD","investigatorTitle":"Professor","investigatorAffiliation":"Capital Medical University"},"leadSponsor":{"name":"Capital Medical University","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Ischemic post-conditioning is a neuroprotective strategy that has been proven to attenuate reperfusion injury in animal models of stroke. The purpose of this proof-of-concept study is to determine the safety and tolerability of ischemic post-conditioning in patients with acute ischemic stroke who are treated with mechanical thrombectomy."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"],"keywords":["acute ischemic stroke","ischemic postconditioning","endovascular thrombectomy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":18,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Ischemic post-conditioning group","type":"EXPERIMENTAL","description":"The safety and tolerability of ischemic post-conditioning will be investigated using 3+3 dose-escalation trial design.","interventionNames":["Procedure: Local ischemic post-conditioning"]}],"interventions":[{"type":"PROCEDURE","name":"Local ischemic post-conditioning","description":"Direct local ischemic post-conditioning will be applied after successful recanalization of the culprit middle cerebral artery. Local ischemic post-conditioning consists of briefly repeated 4 cycles of occlusion and reperfusion (equal duration) of the initially occluded culprit middle cerebral artery using a balloon. The schedule of advancing duration is 0 \" 1 \" 2 \" 3 \" 4 \" 5 min.","armGroupLabels":["Ischemic post-conditioning group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of participants with major response","description":"Major response is any of the following:\n\n* Vessel perforation or rupture;\n* Reocclusion of the culprit vessel after post-conditioning;\n* Vessel dissection;\n* Severe vasospasm;\n* Ischemic post-conditioning related thrombotic events;\n* Rupture of the balloon used for post-conditioning.\n\nIn the 3 + 3 design, 3 subjects are recruited for a given ischemic post-conditioning dose level. The trial is stopped if ≥ 2 of 3 subjects at a given dose level show major response. If only 1 of 3 subjects shows major response, 3 more subjects are recruited at a given dose level and a major response in any of them will stop the trial. Otherwise, same procedure is followed for the next ischemic post-conditioning dose level. Maximum tolerable dose will be the dose at the level before stopping of the trial.","timeFrame":"Immediately after intervention on the day of ischemic post-conditioning"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 18-80 years;\n* Acute ischemic stroke caused by middle cerebral artery M1 segment occlusion;\n* Successful recanalization (mTICI 2b/3) after endovascular thrombectomy that confirmed by digital subtraction angiography;\n* Written informed consent provided by the patients or their legal relatives.\n\nExclusion Criteria:\n\n* Known diagnosis or clinical suspicion of cerebral vasculitis or fibromuscular dysplasia;\n* Difficulty in reaching the designated position of the balloon used for ischemic post-conditioning;\n* Stenting in the middle cerebral artery as rescue therapy during the thrombectomy procedures;\n* \\> 2 times of balloon dilations as rescue therapy due to angioplasty during the thrombectomy procedures;\n* Moderate or severe residual stenosis (≥ 50%) of the culprit artery after recanalization;\n* Difficulty in complying with ischemic post-conditioning or other conditions that the investigator considered inappropriate for inclusion.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Tianjin Huanhu Hospital","city":"Tianjin","state":"Tianjin","zip":"300350","country":"China","geoPoint":{"lat":39.14222,"lon":117.17667}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Related data will be shared if full study protocol and statistical analysis plan are provided with reasonable design."}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}